A Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Repotrectinib in Advanced Cancer Patients

NCT05828277 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Insufficient enrollment

Conditions

Locally Advanced Solid Tumor
Metastatic Solid Tumor

Interventions

DRUG: repotrectinib (TPX-0005)

Sponsor

Turning Point Therapeutics, Inc.